Thomas L A, Veysey M J, Murphy G M, Russell-Jones D, French G L, Wass J A H, Dowling R H
Gastroenterology Unit, Division of Medicine, GKT School of Medicine, Kings College, London, UK.
Gut. 2005 May;54(5):630-5. doi: 10.1136/gut.2003.028431.
Acromegalic patients have slow colonic transit, increased rates of deoxycholic acid formation, and an increased prevalence of cholesterol gall stones, especially during long term octreotide treatment. However, the effects of this prolonged large bowel transit time on the numbers of faecal anaerobes and the activities of the enzyme systems which biotransform conjugated cholic acid into unconjugated deoxycholic acid (cholylglycine hydrolase and 7alpha-dehydroxylase) are unknown.
Therefore, in 10 non-acromegalic controls, 11 acromegalic patients not treated with octreotide, and 11 acromegalics on long term (8-48 months) octreotide (100-200 mug three times daily subcutaneously), we measured large bowel transit time and, in freshly voided faeces, the activities of the two bile acid metabolising enzymes, and related the results to the proportion of deoxycholic acid in fasting serum. Moreover, in patients with acromegaly, we measured quantitative bacteriology in faeces.
Mean large bowel transit time in acromegalics not treated with octreotide (35 (SEM 6.5) hours) was 66% longer than that in non-acromegalic controls (21 (3.1) hours; NS) and became further prolonged during octreotide treatment (48 (6.6) hours; p<0.001). These octreotide induced changes in transit were associated, in acromegalic patients, with more total (15.0 (2.5) v 6.3 (1.3)x10(9) colony forming units (cfu)/g; p<0.05) and Gram positive (6.3 (2.3) v 3.2 (1.0)x10(9) cfu/g; p<0.05) faecal anaerobes. Mean faecal cholylglycine hydrolase activity in the long term octreotide group (22.0 (6.0)x10(-2) U/mg protein) was 138% greater than that in non-acromegalic controls (12.0 (6.0)x10(-2); p<0.01). Similarly, mean 7alpha-dehydroxylase activity in octreotide treated acromegalics (11.1 (1.18)x10(-4) U/mg protein) was 78% greater than that in patients not receiving long term octreotide (6.3 (0.5)x10(-4); p<0.001). The mean proportion of deoxycholic acid in fasting serum also increased from 18.0 (2.88)% in the untreated group to 29.6 (2.3)% during long term octreotide (p<0.05). There were significant linear relationships between large bowel transit time and: (i) faecal 7alpha-dehydroxylase activity; and (ii) the proportion of deoxycholic acid in fasting serum and between 7alpha-dehydroxylase activity and the proportion of deoxycholic acid in serum.Summary/interpretation: These data suggest that increased deoxycholic acid formation seen in acromegalics during octreotide treatment is due not only to the greater numbers of faecal anaerobes but also to increased activity of the rate limiting enzyme pathway (7alpha-dehydroxylation) converting cholic acid to deoxycholic acid.
肢端肥大症患者结肠转运缓慢,脱氧胆酸生成率增加,胆固醇胆结石患病率升高,尤其是在长期使用奥曲肽治疗期间。然而,这种延长的大肠转运时间对粪便厌氧菌数量以及将结合型胆酸转化为非结合型脱氧胆酸的酶系统(胆酰甘氨酸水解酶和7α-脱羟基酶)活性的影响尚不清楚。
因此,我们对10名非肢端肥大症对照者、11名未接受奥曲肽治疗的肢端肥大症患者以及11名长期(8 - 48个月)接受奥曲肽治疗(皮下注射,每日3次,每次100 - 200μg)的肢端肥大症患者,测量了大肠转运时间,并在新鲜排出的粪便中检测了两种胆汁酸代谢酶的活性,并将结果与空腹血清中脱氧胆酸的比例相关联。此外,在肢端肥大症患者中,我们还检测了粪便中的定量细菌学指标。
未接受奥曲肽治疗的肢端肥大症患者的平均大肠转运时间(35(标准误6.5)小时)比非肢端肥大症对照者(21(3.1)小时;无显著性差异)长66%,且在奥曲肽治疗期间进一步延长(48(6.6)小时;p<0.001)。在肢端肥大症患者中,奥曲肽引起的转运变化与粪便中总的厌氧菌数量更多(15.0(2.5)对6.3(1.3)×10⁹菌落形成单位(cfu)/g;p<0.05)以及革兰氏阳性厌氧菌数量更多(6.3(2.3)对3.2(1.0)×10⁹cfu/g;p<0.05)有关。长期奥曲肽治疗组的粪便胆酰甘氨酸水解酶平均活性(22.0(6.0)×10⁻²U/mg蛋白质)比非肢端肥大症对照者(12.0(6.0)×10⁻²;p<0.01)高138%。同样,接受奥曲肽治疗的肢端肥大症患者的7α-脱羟基酶平均活性(11.1(1.18)×10⁻⁴U/mg蛋白质)比未接受长期奥曲肽治疗的患者(6.3(0.5)×10⁻⁴;p<0.001)高78%。空腹血清中脱氧胆酸的平均比例也从未治疗组的18.0(2.88)%增加到长期奥曲肽治疗期间的29.6(2.3)%(p<0.05)。大肠转运时间与以下各项之间存在显著的线性关系:(i)粪便7α-脱羟基酶活性;(ii)空腹血清中脱氧胆酸的比例,以及7α-脱羟基酶活性与血清中脱氧胆酸的比例之间。总结/解读:这些数据表明,肢端肥大症患者在奥曲肽治疗期间脱氧胆酸生成增加不仅是由于粪便厌氧菌数量增多,还与将胆酸转化为脱氧胆酸的限速酶途径(7α-脱羟基化)活性增加有关。